Log in

NASDAQ:CLVSClovis Oncology Stock Price, Forecast & News

-0.21 (-2.92 %)
(As of 06/2/2020 04:00 PM ET)
Today's Range
Now: $6.98
50-Day Range
MA: $8.08
52-Week Range
Now: $6.98
Volume3.75 million shs
Average Volume10.44 million shs
Market Capitalization$536.76 million
P/E RatioN/A
Dividend YieldN/A
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.
Read More
Clovis Oncology logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.1Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.65 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:CLVS



Sales & Book Value

Annual Sales$143.01 million
Book Value($3.17) per share


Net Income$-400,420,000.00
Net Margins-271.13%


Market Cap$536.76 million
Next Earnings Date8/6/2020 (Estimated)

Receive CLVS News and Ratings via Email

Sign-up to receive the latest news and ratings for CLVS and its competitors with MarketBeat's FREE daily newsletter.

Clovis Oncology (NASDAQ:CLVS) Frequently Asked Questions

How has Clovis Oncology's stock been impacted by COVID-19 (Coronavirus)?

Clovis Oncology's stock was trading at $6.17 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CLVS shares have increased by 13.1% and is now trading at $6.98. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Clovis Oncology?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last year. There are currently 2 sell ratings, 5 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Clovis Oncology.

When is Clovis Oncology's next earnings date?

Clovis Oncology is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Clovis Oncology.

How were Clovis Oncology's earnings last quarter?

Clovis Oncology (NASDAQ:CLVS) announced its quarterly earnings results on Tuesday, May, 5th. The biopharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($1.28). The biopharmaceutical company earned $42.56 million during the quarter, compared to analyst estimates of $41.80 million. Clovis Oncology had a negative return on equity of 1,576.32% and a negative net margin of 271.13%. View Clovis Oncology's earnings history.

What price target have analysts set for CLVS?

12 equities research analysts have issued 12 month target prices for Clovis Oncology's stock. Their forecasts range from $4.00 to $36.00. On average, they expect Clovis Oncology's share price to reach $16.63 in the next twelve months. This suggests a possible upside of 138.2% from the stock's current price. View analysts' price targets for Clovis Oncology.

What are Wall Street analysts saying about Clovis Oncology stock?

Here are some recent quotes from research analysts about Clovis Oncology stock:
  • 1. According to Zacks Investment Research, "Clovis reported mixed fourth-quarter results, wherein earnings missed estimates but revenues beat the same. Market share of Clovis’ Rubraca in the ovarian cancer PARP inhibitor market improved in 2019. Approval in second-line maintenance setting for ovarian cancer irrespective of the BRCA-mutation is boosting revenues. Successful development of Rubraca in several ongoing studies, targeting different types of ovarian cancer patients and potential approval for prostate cancer indication are likely to boost the drug’s prospects. The company is actively working on expanding the label of Rubraca. However, Rubraca faces strong competition from other PARP inhibitors in the market, Lynparza and Zejula. Moreover, competition is likely to increase with several others under development. Shares have underperformed the industry in the past year." (4/8/2020)
  • 2. HC Wainwright analysts commented, "Our $36 price target is derived from a sum-of-the-parts analysis based on probability-adjusted revenue forecasts for Rubraca in ovarian cancer combination and prostate cancer indications, and the net present value (NPV) for the current commercial business." (7/3/2019)

Has Clovis Oncology been receiving favorable news coverage?

Press coverage about CLVS stock has trended somewhat negative this week, InfoTrie reports. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Clovis Oncology earned a news sentiment score of -1.6 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutClovis Oncology.

Who are some of Clovis Oncology's key competitors?

What other stocks do shareholders of Clovis Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Clovis Oncology investors own include Gilead Sciences (GILD), Micron Technology (MU), Amarin (AMRN), NVIDIA (NVDA), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Intercept Pharmaceuticals (ICPT), Bristol-Myers Squibb (BMY), Alibaba Group (BABA) and Exelixis (EXEL).

Who are Clovis Oncology's key executives?

Clovis Oncology's management team includes the following people:
  • Mr. Patrick J. Mahaffy MA, Co-Founder, Chief Exec. Officer, Pres and Exec. Director (Age 55)
  • Dr. Gillian C. Ivers-Read BSc, Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations (Age 64)
  • Mr. Daniel W. Muehl CPA, Sr. VP of Fin. and Principal Financial & Accounting Officer (Age 54)
  • Dr. Lindsey Rolfe BSc, MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance (Age 50)
  • Mr. Corwin Dale Hooks, Chief Commercial Officer and Sr. VP (Age 51)

What is Clovis Oncology's stock symbol?

Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."

Who are Clovis Oncology's major shareholders?

Clovis Oncology's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include State Street Corp (4.77%), Geode Capital Management LLC (1.19%), Pinnacle Associates Ltd. (1.09%), SG Americas Securities LLC (0.82%), Sector Gamma AS (0.49%) and Nuveen Asset Management LLC (0.45%). Company insiders that own Clovis Oncology stock include Daniel W Muehl, Gillian C Ivers-Read, James C Blair, Lindsey Rolfe, Patrick J Mahaffy, Paul Edward Gross and Thorlef Spickschen. View institutional ownership trends for Clovis Oncology.

Which institutional investors are selling Clovis Oncology stock?

CLVS stock was sold by a variety of institutional investors in the last quarter, including Soros Fund Management LLC, Rafferty Asset Management LLC, Spark Investment Management LLC, Fisher Asset Management LLC, Sector Gamma AS, Squarepoint Ops LLC, Weiss Multi Strategy Advisers LLC, and New York State Common Retirement Fund. Company insiders that have sold Clovis Oncology company stock in the last year include Daniel W Muehl, Gillian C Ivers-Read, Lindsey Rolfe, and Paul Edward Gross. View insider buying and selling activity for Clovis Oncology.

Which institutional investors are buying Clovis Oncology stock?

CLVS stock was bought by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, BNP Paribas Arbitrage SA, Pinnacle Associates Ltd., Geode Capital Management LLC, Quantitative Investment Management LLC, Redmile Group LLC, Bank of New York Mellon Corp, and Quilter Plc. Company insiders that have bought Clovis Oncology stock in the last two years include James C Blair, Patrick J Mahaffy, and Thorlef Spickschen. View insider buying and selling activity for Clovis Oncology.

How do I buy shares of Clovis Oncology?

Shares of CLVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Clovis Oncology's stock price today?

One share of CLVS stock can currently be purchased for approximately $6.98.

How big of a company is Clovis Oncology?

Clovis Oncology has a market capitalization of $536.76 million and generates $143.01 million in revenue each year. The biopharmaceutical company earns $-400,420,000.00 in net income (profit) each year or ($7.60) on an earnings per share basis.

What is Clovis Oncology's official website?

The official website for Clovis Oncology is www.clovisoncology.com.

How can I contact Clovis Oncology?

Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The biopharmaceutical company can be reached via phone at 303-625-5000 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.